2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 548

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Abstract Number: 1543

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
Abstract Number: 1572

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Abstract Number: 1267

Are Anti-SRP Auto-Antibodies Specific for Myositis?
Abstract Number: 2523

Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Abstract Number: 140

Are Entheses Ultrasound Findings Similar in Axial Spa Patients and in Athletes?
Abstract Number: 1365

ARE Erosions a Disappearing Feature in Rheumatoid Arthritis (RA)?Joint Damage in Patients with EARLY RA at 10 YEARS after Diagnosis
Abstract Number: 1789

Are EULAR/Printo/PRES Classification Criteria Appropriate for Classification of IgA Vasculitis in Adults?
Abstract Number: 2084

Are Genetic Markers Associated with Myocardial Infarction in Patients with Early Rheumatoid Arthritis?
Abstract Number: 1802

Are Outcomes after Total Knee Arthroplasty Worsening over Time? a Time-Trends Study of Activity Limitation and Pain Outcomes
Abstract Number: 2109

Are Patient Ratings of Providers and Health Plans Associated with Technical Quality of Care in SLE?
Abstract Number: 2519

Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF?
Abstract Number: 1661

Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares?
Abstract Number: 1368

Are Tender Joints Better Than Synovitis to Predict Structural Damage in Rheumatoid Arthritis?
Abstract Number: 1601

Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].